|
Vol. 4 • Issue 4 • Page 41
1. Umesh, K.N., Monica, K.B., et. al., Prevalence of conventional risk factors in patients with coronary heart disease. Journal of American Medical Association. 2003 Aug; 7(290): 898-904.
2. Toppy, J.M., Cassio, L., Glass, R.M. Risk factors for heart disease. Journal of the American Medical Association. 2003 Aug; 290: 980.
3. Graeme, H.J. Potential new risk factors for ischemic stroke: what is their potential? Stroke. 2006; 37: 2181-2188.
4. Haapanen-Niemi, N., Miilunpalo, S., et. al., Body mass index; physical inactivity and low level of physical fitness as determinants of all-cause and cardiovascular disease mortality-164 follow up of middle-aged and elderly men and women. International Journal of Obesity and Related Metabolic Disorders. 2000 Nov; 24(11): 1465-1474.
5. Carter, M. Heart Disease Still the Most Likely Reason You'll Die. CNN.com health 2006 Nov. Found online at: www.cnn.com/2006/health/10/30/heartoverview/ing.
6. Cene, C.W., Yanek, L.R., et. al., Sustainability of a multiple risk factor intervention on cardiovascular disease in high-risk African American families. Ethnicity and Disease. 2008; 18(2): 169-175.
7. Dixon, J.B., O'Brien, P.F., et. al., Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. Journal of American Medical Association. 2008 Jan; 299(3): 316-323.
8. Corr, L. New methods of making blocked coronary arteries patent again. British Journal of Medicine. 1994 Sept; 309(6954): 579-583
9. Hennekens, C.H. Fixed dose combination therapy with statins: strengths, limitations, and clinical and regulatory considerations. American Journal of Cardiovascular Drugs. 2008; 8(3): 155-160.
10. Langsjoen, P.H., Langsjown, A.M. Overview of the use of CoQ10 in heart disease. Cardiovascular Disease Biofactors. 1999; 9: 273-285.
11. Littarru, Gian Paolo, et. al., Clinical aspects of coenzyme Q: Improvement of cellular bioenergetics or antioxidant protection? In Handbook of Antioxidants, Eds. Enrique Cadenas, Lester Parker, New York: Marcel Dekker, Inc. 1996, pp. 203-239.
12. Lampertico, M., Comis, S. Italian multicenter study on the efficiency and safety of coenzyme Q10 as an adjuvant therapy in heart failure. Clinical Investigations. 1993; 71: S129-S133.
13. Hofman-Bang, C., Rehnquist, N., et. al., CoQ10 as an adjuctive treatment for congestive heart failure. Journal American College of Cardiology. 1992; 19: 216A.
14. Crane, F.L., Hatefi, Y., Lester, R.L., et. al., Isolation of quinone from beef heart mitochondria. Biochemical Biophysics Acta. 1957 July; 25(1): 220-221.
15. Ross, S.M. Coenzyme Q10: ubiquinone: a potent antioxidant and key energy facilitator for the heart. Itolistic Nursing Practice. 2007 July-Aug; 21(4): 213-214.
16. Greenberg, S., Frishman, W.H. Co-enzyme Q10: a new drug for cardiovascular disease. Journal of Clinical Pharmacology. 1990; 30: 596-608.
17. Ohara, H., Kanaide, H., e. al., A protective effect of coenzyme Q10 on ischemia and reperfusion of isolated perfused rat heart. Journal of Molecular Cell Cardiology. 1981; 13: 65-82.
18. Caplan, A.I., Greenwait, J.W. Biochemical and ultrastructural properties of osmotically lysed rat-liver mitochondria. Journal of Cell Biology. 1996 Dec; 31(3): 455-472.
19. Litarru, G.P., Tiano, L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Molecular Biotechnology. 2007 Sept; 37(1): 31-37.
20. Guyton, A.C. Function of the Human Body. Philadelphia, PA: 1969, p.25-26.
21. Bliznakov, E.G., The Miracle Nutrient CoEnzyme Q10. New York: Bantam Books, 1989.
22. Fargo, P., Lagnado, J. Life In Action. New York: Alfred A. Knopf, 1972, p.99.
23. Passwater, R.A. Coenzyme Q10 and heart disease: an interview with Dr. Stephen Sinatra: Part 2: The magic of CoQ10. South Plainfield, NJ Whole Foods Magazine. March 2004; p. 64-70.
24. Folkers, K., Littarru, G.P., Ho., L., et. al., Evidence for a deficiency of coenzyme Q10 in human heart disease. International Z. Vitamin Forsch. 1970; 40(3): 389-390.
25. Harinstein, M.E., Berliner, J.T., et. al., Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observation in 11 patients. American Journal of Therapeutics. 2008 May-June; 15(3): 206-213.
26. Mohan, S.B., Parker, M., et. al., Idiopathic dialted cardiomyopathy: A common but mystifying cause of heart failure. Cleveland Clinic Journal of Medicine. 2002 June; 69(6): 481-487.
27. Jankharia, B. CMR in myocardial viability. The Internet Journal of Cardiology. 2004; 4(2) Found online at: www.ispub.com/ostia/index:php?sm/filepath=jouna Accessed on 06/26/08.
28. University of Rochester Medical Center - Division of Cardiac Surgery, Coronary Revascularization. Found online at: www.stronghealth.com/services/surgical/cardiotho Accessed on 06/26/08.
29. Takeo, S., Sakanashi, M. Possible mechanisms for reoxygeneration-induced recovery of myocardial high-energy phosphates after hypoxia. Journal of Molecular and Cell Cardiology. 1983 Sept; 15(9): 577-594.
30. Aggarwal, R., Ahearne, D., et. al., The Bantam Medical Dictionary. 5th Ed. New York: NY, 2004.
31. Takeo, S., Tanonaka, K., et. al., Role of ATP metabolites in induction of incomplete recovery of cardiac contractile force after hypoxia. Canadian Journal of Cardiology. 1988 May; 4(4): 193-200.
32. Medline Plus Medical Encyclopedia: Creatine Phosphokinase. National Institute of Health. Found online at: www.nih.gov/medlineplus/ency/article/003503 Accessed on 06/26/08.
33. Taken, S., Tanonaka, K., et. al., Possible mechanism by which coenzyme Q10 improves reoxygeneration-induced recovery of cardiac contractile force after hypoxia. Journal of Pharmacology and Experiemental Therapy. 1987 Dec; 243(3): 1131-1138.
34. Koh, K.K., Quon, M.J., Waclawiw, M.A. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis. 2008 Jan; 196(1):8.
35. Coppola, G., Novo, S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Archives of Medicals Research. 2007 July; 38(5): 479-488.
36. Albaeb, M.E., Alobaid, N., et. al., Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Annals of Vascular Surgery. 2006 Sept; 20(5): 696-705.
37. Edwards, K.L., Mahaney, M.C., et. al., Pleitropic genetic effects of LDL size, plasma, triglyceride and HDL cholesterol in families. Arteriosclerosis, Thrombosis and Vascular Biology. 1999 Oct; 19(10): 2456-2464.
38. Marcoff, L., Thompson, P.D., The role of Q10 in statin-associated myopathy: a systematic review. Journal of American College of Cardiology. 2007; 49(23): 2231-2237
39. Levy, H.B., Kohlhaas, H.K. Considerations for supplementing with coenzyme Q10 during statin therapy. The Annals of Pharmacotherapy. 2006 Feb; 40(2): 290-294.
40. Sinatra, S.T. The Coenzyme Q10 Phenomenon. Chicago, IL: Keats Publishing, 1998.
41. Rakoczi, K., Pardutz, A., Vecsei, L. Statin drugs decrease the plasma level of coenzyme Q10 (ubiquinone) in the organism. Idegsyogy Aszati Szemle. 2007 July; 60(7-8): 295-300.
42. Silver, M.A., Langsjoen, P.H., et. al., Effect of atorvastain on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfuction. American Journal of Cardiology. 2004 Nov; 94(10): 1306-1310.
43. Silver, M.A., Langsjoen, P.H., et. al., Statin cardiomyopathy: a potential role for coenzyme Q10 therapy for statin induced changes in diastolic LV performance: description of a clinical protocol. Biofactors. 2003; 18(1-4): 125-127.
44. Langsjoen, P.H. Alleviating congestive heart failure with coenzyme Q10. Life Extension. 2008 Feb-March; 57-63.
45. Langsjoen, P.H., Langsjoen, J.O., et. al., Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation. Biofactors. 2005; 25(1-4): 147-152.
46. Littarru, G.P., Langsjoen, P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007 June; 7 Suppl: S168-S174.
47. Berman, M., Erman, A., et. al., Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology. 2004 May; 27(5): 295-299.
48. Mortensen, S.A. Overview on coenzyme Q10 as a adjunctive therapy in chronic heart failure: rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors. 2003; 18(1-4): 79-89.
49. Chopra, R.K., Goldman, R., Sinatra, S.T., et. al., Relative bioavailability of coenzyme Q10 formulations in human subjects. International Journal of Vitamin and Nutrition Research. 1998; 68: 109-113.
50. Digiesi, V., Cantini, F., et. al., Mechanism of action of coenzyme Q10 in essential hypertension. 1992; 51: 668-772.
51. Folkers, K., et. al., Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proceedings of National Academy of Sciences, USA. 1985; 82: 4513.
52. Folkers, K., et. al., Coenzyme Q10 increases Ty/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochemical and Biophysical Research Communications. 1991 April; 176: 786-791.
53. Marincola, R., Neurobiology and quantified pharmaco EEG of coenzyme Q10. Journal of Orthomolecular Medicine. 1997; 12(2): 87-95.
54. Modi, K., Santani, D., et. al., Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin-induced diabetic rats. Biological Trace Element Research. 2006 Jan; 109(1): 25-34.
55. Perumal, S.S., Shanthi, P., et. al., Combined efficacy of tamoxifen and coenzyme Q10 on the status of lipid peroxidation and antioxidants in DMBA induced breast cancer. Molecular and Cellular Biochemistry. 2005 May; 273(1-2): 151-160.
56. Hodgson, J.M., Watts, G.F., et. al., Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition. 2002 Nov; 56(11): 1137-1142.
57. Ely, J.T., Krone, C.A. A brief update on ubiquinone (coenzyme Q10). Journal of Orthomolecular Me
|